Related references
Note: Only part of the references are listed.Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents
Shuku Sato et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)
Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma
Tiancheng Luo et al.
BLOOD SCIENCE (2021)
Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma
Tiancheng Luo et al.
BLOOD SCIENCE (2021)
Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance
Mehmet Baysal et al.
SCIENTIFIC REPORTS (2020)
Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Hiroyuki Takamatsu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Ja Min Byun et al.
IN VIVO (2019)
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma
G. P. Kaufman et al.
LEUKEMIA (2016)
Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death
Philippe Moreau et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial
Pavel Nemec et al.
LEUKEMIA & LYMPHOMA (2012)
Genomic Aberrations and Survival of Patients with Light-Chain-Only Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Nan Jiang et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation
H. Greslikova et al.
NEOPLASMA (2010)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
P. Moreau et al.
LEUKEMIA (2007)
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
N. C. Gutierrez et al.
LEUKEMIA (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy
MA Gertz et al.
BLOOD (2005)
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
H Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Share Paper
